nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—thymus cancer	0.441	1	CtDrD
Crizotinib—MUSK—thymus cancer	0.409	1	CbGaD
Crizotinib—Sinus bradycardia—Octreotide—thymus cancer	0.00205	0.0826	CcSEcCtD
Crizotinib—Transaminases increased—Octreotide—thymus cancer	0.00165	0.0666	CcSEcCtD
Crizotinib—Burning sensation—Octreotide—thymus cancer	0.00144	0.0583	CcSEcCtD
Crizotinib—Neuralgia—Octreotide—thymus cancer	0.00144	0.0583	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Octreotide—thymus cancer	0.001	0.0405	CcSEcCtD
Crizotinib—Neuropathy—Octreotide—thymus cancer	0.000942	0.038	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.000838	0.0338	CcSEcCtD
Crizotinib—Visual disturbance—Octreotide—thymus cancer	0.000769	0.031	CcSEcCtD
Crizotinib—Muscular weakness—Octreotide—thymus cancer	0.000643	0.0259	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Octreotide—thymus cancer	0.000585	0.0236	CcSEcCtD
Crizotinib—Weight decreased—Octreotide—thymus cancer	0.00057	0.023	CcSEcCtD
Crizotinib—Pneumonia—Octreotide—thymus cancer	0.000565	0.0228	CcSEcCtD
Crizotinib—Neuropathy peripheral—Octreotide—thymus cancer	0.00055	0.0222	CcSEcCtD
Crizotinib—Hepatobiliary disease—Octreotide—thymus cancer	0.000531	0.0214	CcSEcCtD
Crizotinib—Bradycardia—Octreotide—thymus cancer	0.000513	0.0207	CcSEcCtD
Crizotinib—Hypoaesthesia—Octreotide—thymus cancer	0.000501	0.0202	CcSEcCtD
Crizotinib—Oedema peripheral—Octreotide—thymus cancer	0.000496	0.02	CcSEcCtD
Crizotinib—Visual impairment—Octreotide—thymus cancer	0.000486	0.0196	CcSEcCtD
Crizotinib—Cardiac disorder—Octreotide—thymus cancer	0.000468	0.0189	CcSEcCtD
Crizotinib—Arrhythmia—Octreotide—thymus cancer	0.00045	0.0182	CcSEcCtD
Crizotinib—Malnutrition—Octreotide—thymus cancer	0.000439	0.0177	CcSEcCtD
Crizotinib—Vision blurred—Octreotide—thymus cancer	0.000413	0.0167	CcSEcCtD
Crizotinib—Anaemia—Octreotide—thymus cancer	0.000405	0.0164	CcSEcCtD
Crizotinib—Syncope—Octreotide—thymus cancer	0.000393	0.0159	CcSEcCtD
Crizotinib—Loss of consciousness—Octreotide—thymus cancer	0.000386	0.0156	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000371	0.015	CcSEcCtD
Crizotinib—Oedema—Octreotide—thymus cancer	0.000358	0.0145	CcSEcCtD
Crizotinib—Infection—Octreotide—thymus cancer	0.000356	0.0144	CcSEcCtD
Crizotinib—Shock—Octreotide—thymus cancer	0.000352	0.0142	CcSEcCtD
Crizotinib—Nervous system disorder—Octreotide—thymus cancer	0.000351	0.0142	CcSEcCtD
Crizotinib—Skin disorder—Octreotide—thymus cancer	0.000348	0.014	CcSEcCtD
Crizotinib—Paraesthesia—Octreotide—thymus cancer	0.000322	0.013	CcSEcCtD
Crizotinib—Dyspnoea—Octreotide—thymus cancer	0.000319	0.0129	CcSEcCtD
Crizotinib—Dyspepsia—Octreotide—thymus cancer	0.000315	0.0127	CcSEcCtD
Crizotinib—Decreased appetite—Octreotide—thymus cancer	0.000311	0.0126	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000309	0.0125	CcSEcCtD
Crizotinib—Fatigue—Octreotide—thymus cancer	0.000309	0.0125	CcSEcCtD
Crizotinib—Constipation—Octreotide—thymus cancer	0.000306	0.0124	CcSEcCtD
Crizotinib—Body temperature increased—Octreotide—thymus cancer	0.000283	0.0114	CcSEcCtD
Crizotinib—Asthenia—Octreotide—thymus cancer	0.000257	0.0104	CcSEcCtD
Crizotinib—Diarrhoea—Octreotide—thymus cancer	0.000245	0.00989	CcSEcCtD
Crizotinib—Dizziness—Octreotide—thymus cancer	0.000237	0.00956	CcSEcCtD
Crizotinib—Vomiting—Octreotide—thymus cancer	0.000228	0.00919	CcSEcCtD
Crizotinib—Rash—Octreotide—thymus cancer	0.000226	0.00911	CcSEcCtD
Crizotinib—Dermatitis—Octreotide—thymus cancer	0.000226	0.00911	CcSEcCtD
Crizotinib—Nausea—Octreotide—thymus cancer	0.000213	0.00859	CcSEcCtD
Crizotinib—RIPK2—cardiac atrium—thymus cancer	0.00017	0.0025	CbGeAlD
Crizotinib—AURKA—thyroid gland—thymus cancer	0.00017	0.0025	CbGeAlD
Crizotinib—EPHA2—epithelium—thymus cancer	0.00017	0.0025	CbGeAlD
Crizotinib—ALK—lung—thymus cancer	0.00017	0.00249	CbGeAlD
Crizotinib—FER—lung—thymus cancer	0.00017	0.00249	CbGeAlD
Crizotinib—TESK1—thyroid gland—thymus cancer	0.000169	0.00248	CbGeAlD
Crizotinib—LIMK1—lymph node—thymus cancer	0.000168	0.00247	CbGeAlD
Crizotinib—TNK1—lung—thymus cancer	0.000168	0.00247	CbGeAlD
Crizotinib—YES1—hematopoietic system—thymus cancer	0.000168	0.00246	CbGeAlD
Crizotinib—RIPK2—pituitary gland—thymus cancer	0.000166	0.00245	CbGeAlD
Crizotinib—BMPR1B—lung—thymus cancer	0.000166	0.00244	CbGeAlD
Crizotinib—MAP4K1—lung—thymus cancer	0.000166	0.00244	CbGeAlD
Crizotinib—MAP3K19—lung—thymus cancer	0.000166	0.00244	CbGeAlD
Crizotinib—STK10—hematopoietic system—thymus cancer	0.000166	0.00244	CbGeAlD
Crizotinib—TEK—epithelium—thymus cancer	0.000166	0.00244	CbGeAlD
Crizotinib—TAOK3—hematopoietic system—thymus cancer	0.000165	0.00243	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—thymus cancer	0.000165	0.00242	CbGeAlD
Crizotinib—MERTK—bone marrow—thymus cancer	0.000165	0.00242	CbGeAlD
Crizotinib—MERTK—thyroid gland—thymus cancer	0.000164	0.00241	CbGeAlD
Crizotinib—PRKD3—lymph node—thymus cancer	0.000164	0.00241	CbGeAlD
Crizotinib—IGF1R—lung—thymus cancer	0.000163	0.0024	CbGeAlD
Crizotinib—TNK2—lung—thymus cancer	0.000163	0.0024	CbGeAlD
Crizotinib—SRC—hematopoietic system—thymus cancer	0.000161	0.00237	CbGeAlD
Crizotinib—EPHA4—pituitary gland—thymus cancer	0.000161	0.00236	CbGeAlD
Crizotinib—MAP4K2—lung—thymus cancer	0.000161	0.00236	CbGeAlD
Crizotinib—LIMK2—thyroid gland—thymus cancer	0.000161	0.00236	CbGeAlD
Crizotinib—NUAK2—bone marrow—thymus cancer	0.00016	0.00236	CbGeAlD
Crizotinib—DSTYK—lymph node—thymus cancer	0.00016	0.00235	CbGeAlD
Crizotinib—NUAK2—thyroid gland—thymus cancer	0.00016	0.00235	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—thymus cancer	0.000159	0.00234	CbGeAlD
Crizotinib—ACVR1—bone marrow—thymus cancer	0.000159	0.00234	CbGeAlD
Crizotinib—FLT3—bone marrow—thymus cancer	0.000159	0.00234	CbGeAlD
Crizotinib—ACVR1—thyroid gland—thymus cancer	0.000159	0.00233	CbGeAlD
Crizotinib—MAP3K12—thyroid gland—thymus cancer	0.000159	0.00233	CbGeAlD
Crizotinib—TIE1—lung—thymus cancer	0.000159	0.00233	CbGeAlD
Crizotinib—STK3—lung—thymus cancer	0.000159	0.00233	CbGeAlD
Crizotinib—BLK—lymph node—thymus cancer	0.000158	0.00233	CbGeAlD
Crizotinib—TBK1—cardiac atrium—thymus cancer	0.000158	0.00232	CbGeAlD
Crizotinib—TYK2—cardiac atrium—thymus cancer	0.000157	0.00231	CbGeAlD
Crizotinib—LTK—lymph node—thymus cancer	0.000156	0.0023	CbGeAlD
Crizotinib—CASK—lymph node—thymus cancer	0.000156	0.0023	CbGeAlD
Crizotinib—STK35—thyroid gland—thymus cancer	0.000156	0.00229	CbGeAlD
Crizotinib—AURKA—lung—thymus cancer	0.000155	0.00227	CbGeAlD
Crizotinib—PTK2—pituitary gland—thymus cancer	0.000155	0.00227	CbGeAlD
Crizotinib—TBK1—pituitary gland—thymus cancer	0.000155	0.00227	CbGeAlD
Crizotinib—TYK2—pituitary gland—thymus cancer	0.000154	0.00226	CbGeAlD
Crizotinib—TESK1—lung—thymus cancer	0.000153	0.00225	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—thymus cancer	0.000152	0.00224	CbGeAlD
Crizotinib—ABL2—thyroid gland—thymus cancer	0.000152	0.00223	CbGeAlD
Crizotinib—MAPK7—lymph node—thymus cancer	0.000152	0.00223	CbGeAlD
Crizotinib—TXK—lymph node—thymus cancer	0.000152	0.00223	CbGeAlD
Crizotinib—AXL—cardiac atrium—thymus cancer	0.000151	0.00221	CbGeAlD
Crizotinib—BMP2K—bone marrow—thymus cancer	0.00015	0.00221	CbGeAlD
Crizotinib—FES—lymph node—thymus cancer	0.00015	0.0022	CbGeAlD
Crizotinib—BMP2K—thyroid gland—thymus cancer	0.00015	0.0022	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—thymus cancer	0.00015	0.0022	CbGeAlD
Crizotinib—MERTK—lung—thymus cancer	0.000149	0.00219	CbGeAlD
Crizotinib—RPS6KB1—pituitary gland—thymus cancer	0.000149	0.00218	CbGeAlD
Crizotinib—FGR—pituitary gland—thymus cancer	0.000148	0.00217	CbGeAlD
Crizotinib—SRC—epithelium—thymus cancer	0.000147	0.00217	CbGeAlD
Crizotinib—AXL—pituitary gland—thymus cancer	0.000147	0.00216	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—thymus cancer	0.000147	0.00216	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—thymus cancer	0.000147	0.00216	CbGeAlD
Crizotinib—LIMK2—lung—thymus cancer	0.000146	0.00214	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—thymus cancer	0.000146	0.00214	CbGeAlD
Crizotinib—NUAK2—lung—thymus cancer	0.000145	0.00213	CbGeAlD
Crizotinib—PTK2B—bone marrow—thymus cancer	0.000145	0.00213	CbGeAlD
Crizotinib—SLK—cardiac atrium—thymus cancer	0.000145	0.00213	CbGeAlD
Crizotinib—CSF1R—hematopoietic system—thymus cancer	0.000145	0.00213	CbGeAlD
Crizotinib—PTK2B—thyroid gland—thymus cancer	0.000145	0.00213	CbGeAlD
Crizotinib—FLT3—lung—thymus cancer	0.000144	0.00212	CbGeAlD
Crizotinib—MAP3K12—lung—thymus cancer	0.000144	0.00212	CbGeAlD
Crizotinib—ACVR1—lung—thymus cancer	0.000144	0.00212	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—thymus cancer	0.000144	0.00212	CbGeAlD
Crizotinib—RIPK2—bone marrow—thymus cancer	0.000144	0.00211	CbGeAlD
Crizotinib—RIPK2—thyroid gland—thymus cancer	0.000143	0.00211	CbGeAlD
Crizotinib—JAK2—cardiac atrium—thymus cancer	0.000143	0.0021	CbGeAlD
Crizotinib—MET—lymph node—thymus cancer	0.000142	0.00208	CbGeAlD
Crizotinib—SLK—pituitary gland—thymus cancer	0.000142	0.00208	CbGeAlD
Crizotinib—STK35—lung—thymus cancer	0.000141	0.00208	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—thymus cancer	0.000141	0.00208	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—thymus cancer	0.000141	0.00207	CbGeAlD
Crizotinib—EPHB4—pituitary gland—thymus cancer	0.000141	0.00207	CbGeAlD
Crizotinib—FGR—lymphoid tissue—thymus cancer	0.00014	0.00206	CbGeAlD
Crizotinib—AXL—lymphoid tissue—thymus cancer	0.00014	0.00205	CbGeAlD
Crizotinib—JAK2—pituitary gland—thymus cancer	0.00014	0.00205	CbGeAlD
Crizotinib—EPHA4—thyroid gland—thymus cancer	0.000139	0.00204	CbGeAlD
Crizotinib—EPHA2—pituitary gland—thymus cancer	0.000138	0.00203	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—thymus cancer	0.000138	0.00202	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—thymus cancer	0.000138	0.00202	CbGeAlD
Crizotinib—TEK—cardiac atrium—thymus cancer	0.000138	0.00202	CbGeAlD
Crizotinib—ABL2—lung—thymus cancer	0.000138	0.00202	CbGeAlD
Crizotinib—CDK7—lymph node—thymus cancer	0.000137	0.00202	CbGeAlD
Crizotinib—MAP3K2—bone marrow—thymus cancer	0.000136	0.002	CbGeAlD
Crizotinib—TAOK2—lymph node—thymus cancer	0.000136	0.002	CbGeAlD
Crizotinib—BMP2K—lung—thymus cancer	0.000136	0.002	CbGeAlD
Crizotinib—MAP3K2—thyroid gland—thymus cancer	0.000136	0.002	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—thymus cancer	0.000135	0.00198	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—thymus cancer	0.000135	0.00198	CbGeAlD
Crizotinib—TEK—pituitary gland—thymus cancer	0.000135	0.00198	CbGeAlD
Crizotinib—TBK1—bone marrow—thymus cancer	0.000134	0.00196	CbGeAlD
Crizotinib—PTK2—thyroid gland—thymus cancer	0.000133	0.00196	CbGeAlD
Crizotinib—TBK1—thyroid gland—thymus cancer	0.000133	0.00196	CbGeAlD
Crizotinib—TYK2—bone marrow—thymus cancer	0.000133	0.00195	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—thymus cancer	0.000133	0.00195	CbGeAlD
Crizotinib—TYK2—thyroid gland—thymus cancer	0.000132	0.00194	CbGeAlD
Crizotinib—EPHB6—cardiac atrium—thymus cancer	0.000132	0.00193	CbGeAlD
Crizotinib—PTK2B—lung—thymus cancer	0.000131	0.00193	CbGeAlD
Crizotinib—ACVR1B—lymph node—thymus cancer	0.000131	0.00193	CbGeAlD
Crizotinib—EPHA3—lymph node—thymus cancer	0.000131	0.00193	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—thymus cancer	0.000131	0.00192	CbGeAlD
Crizotinib—IRAK1—bone marrow—thymus cancer	0.000131	0.00192	CbGeAlD
Crizotinib—IRAK1—thyroid gland—thymus cancer	0.000131	0.00192	CbGeAlD
Crizotinib—RIPK2—lung—thymus cancer	0.00013	0.00191	CbGeAlD
Crizotinib—EPHB6—pituitary gland—thymus cancer	0.000129	0.00189	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—thymus cancer	0.000128	0.00189	CbGeAlD
Crizotinib—RPS6KB1—thyroid gland—thymus cancer	0.000128	0.00188	CbGeAlD
Crizotinib—TEK—lymphoid tissue—thymus cancer	0.000128	0.00188	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—thymus cancer	0.000128	0.00188	CbGeAlD
Crizotinib—FGR—bone marrow—thymus cancer	0.000128	0.00188	CbGeAlD
Crizotinib—LCK—bone marrow—thymus cancer	0.000128	0.00188	CbGeAlD
Crizotinib—FGR—thyroid gland—thymus cancer	0.000127	0.00187	CbGeAlD
Crizotinib—LCK—thyroid gland—thymus cancer	0.000127	0.00187	CbGeAlD
Crizotinib—YES1—cardiac atrium—thymus cancer	0.000127	0.00187	CbGeAlD
Crizotinib—AXL—thyroid gland—thymus cancer	0.000127	0.00186	CbGeAlD
Crizotinib—EPHA4—lung—thymus cancer	0.000126	0.00185	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—thymus cancer	0.000126	0.00185	CbGeAlD
Crizotinib—JAK3—lymph node—thymus cancer	0.000125	0.00184	CbGeAlD
Crizotinib—DCLK1—lymph node—thymus cancer	0.000124	0.00183	CbGeAlD
Crizotinib—YES1—pituitary gland—thymus cancer	0.000124	0.00183	CbGeAlD
Crizotinib—MAP3K2—lung—thymus cancer	0.000124	0.00182	CbGeAlD
Crizotinib—PLK4—lymph node—thymus cancer	0.000124	0.00182	CbGeAlD
Crizotinib—STK4—lymph node—thymus cancer	0.000123	0.0018	CbGeAlD
Crizotinib—TAOK3—pituitary gland—thymus cancer	0.000123	0.0018	CbGeAlD
Crizotinib—SLK—bone marrow—thymus cancer	0.000122	0.0018	CbGeAlD
Crizotinib—SRC—cardiac atrium—thymus cancer	0.000122	0.0018	CbGeAlD
Crizotinib—SLK—thyroid gland—thymus cancer	0.000122	0.00179	CbGeAlD
Crizotinib—EPHB4—bone marrow—thymus cancer	0.000122	0.00179	CbGeAlD
Crizotinib—EPHB4—thyroid gland—thymus cancer	0.000121	0.00178	CbGeAlD
Crizotinib—PTK2—lung—thymus cancer	0.000121	0.00178	CbGeAlD
Crizotinib—TBK1—lung—thymus cancer	0.000121	0.00178	CbGeAlD
Crizotinib—JAK2—bone marrow—thymus cancer	0.000121	0.00177	CbGeAlD
Crizotinib—JAK2—thyroid gland—thymus cancer	0.00012	0.00177	CbGeAlD
Crizotinib—TYK2—lung—thymus cancer	0.00012	0.00177	CbGeAlD
Crizotinib—EPHA2—thyroid gland—thymus cancer	0.000119	0.00175	CbGeAlD
Crizotinib—IRAK1—lung—thymus cancer	0.000119	0.00174	CbGeAlD
Crizotinib—YES1—lymphoid tissue—thymus cancer	0.000118	0.00173	CbGeAlD
Crizotinib—STK10—lymphoid tissue—thymus cancer	0.000117	0.00172	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—thymus cancer	0.000116	0.00171	CbGeAlD
Crizotinib—RPS6KB1—lung—thymus cancer	0.000116	0.00171	CbGeAlD
Crizotinib—MAP3K3—bone marrow—thymus cancer	0.000116	0.00171	CbGeAlD
Crizotinib—MAP4K5—bone marrow—thymus cancer	0.000116	0.00171	CbGeAlD
Crizotinib—ALK—lymph node—thymus cancer	0.000116	0.00171	CbGeAlD
Crizotinib—FER—lymph node—thymus cancer	0.000116	0.00171	CbGeAlD
Crizotinib—MAP4K5—thyroid gland—thymus cancer	0.000116	0.0017	CbGeAlD
Crizotinib—MAP3K3—thyroid gland—thymus cancer	0.000116	0.0017	CbGeAlD
Crizotinib—TEK—thyroid gland—thymus cancer	0.000116	0.0017	CbGeAlD
Crizotinib—FGR—lung—thymus cancer	0.000116	0.0017	CbGeAlD
Crizotinib—LCK—lung—thymus cancer	0.000116	0.0017	CbGeAlD
Crizotinib—AXL—lung—thymus cancer	0.000115	0.00169	CbGeAlD
Crizotinib—TNK1—lymph node—thymus cancer	0.000115	0.00169	CbGeAlD
Crizotinib—ABL1—hematopoietic system—thymus cancer	0.000114	0.00168	CbGeAlD
Crizotinib—BMPR1B—lymph node—thymus cancer	0.000114	0.00167	CbGeAlD
Crizotinib—MAP4K1—lymph node—thymus cancer	0.000114	0.00167	CbGeAlD
Crizotinib—SRC—lymphoid tissue—thymus cancer	0.000114	0.00167	CbGeAlD
Crizotinib—TNK2—lymph node—thymus cancer	0.000112	0.00164	CbGeAlD
Crizotinib—IGF1R—lymph node—thymus cancer	0.000112	0.00164	CbGeAlD
Crizotinib—SLK—lung—thymus cancer	0.000111	0.00163	CbGeAlD
Crizotinib—EPHB6—thyroid gland—thymus cancer	0.000111	0.00163	CbGeAlD
Crizotinib—EPHB4—lung—thymus cancer	0.00011	0.00162	CbGeAlD
Crizotinib—MAP4K2—lymph node—thymus cancer	0.00011	0.00162	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—thymus cancer	0.00011	0.00161	CbGeAlD
Crizotinib—JAK2—lung—thymus cancer	0.000109	0.00161	CbGeAlD
Crizotinib—STK3—lymph node—thymus cancer	0.000108	0.00159	CbGeAlD
Crizotinib—TIE1—lymph node—thymus cancer	0.000108	0.00159	CbGeAlD
Crizotinib—EPHA2—lung—thymus cancer	0.000108	0.00159	CbGeAlD
Crizotinib—YES1—bone marrow—thymus cancer	0.000107	0.00158	CbGeAlD
Crizotinib—CSF1R—pituitary gland—thymus cancer	0.000107	0.00158	CbGeAlD
Crizotinib—YES1—thyroid gland—thymus cancer	0.000107	0.00157	CbGeAlD
Crizotinib—STK10—bone marrow—thymus cancer	0.000106	0.00156	CbGeAlD
Crizotinib—STK10—thyroid gland—thymus cancer	0.000106	0.00156	CbGeAlD
Crizotinib—TAOK3—bone marrow—thymus cancer	0.000106	0.00156	CbGeAlD
Crizotinib—TAOK3—thyroid gland—thymus cancer	0.000106	0.00155	CbGeAlD
Crizotinib—AURKA—lymph node—thymus cancer	0.000106	0.00155	CbGeAlD
Crizotinib—MAP3K3—lung—thymus cancer	0.000105	0.00155	CbGeAlD
Crizotinib—MAP4K5—lung—thymus cancer	0.000105	0.00155	CbGeAlD
Crizotinib—TEK—lung—thymus cancer	0.000105	0.00155	CbGeAlD
Crizotinib—TESK1—lymph node—thymus cancer	0.000105	0.00154	CbGeAlD
Crizotinib—SRC—thyroid gland—thymus cancer	0.000103	0.00151	CbGeAlD
Crizotinib—MERTK—lymph node—thymus cancer	0.000102	0.0015	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—thymus cancer	0.000102	0.0015	CbGeAlD
Crizotinib—EPHB6—lung—thymus cancer	0.000101	0.00148	CbGeAlD
Crizotinib—LIMK2—lymph node—thymus cancer	9.97e-05	0.00147	CbGeAlD
Crizotinib—NUAK2—lymph node—thymus cancer	9.94e-05	0.00146	CbGeAlD
Crizotinib—MAP3K12—lymph node—thymus cancer	9.87e-05	0.00145	CbGeAlD
Crizotinib—ACVR1—lymph node—thymus cancer	9.87e-05	0.00145	CbGeAlD
Crizotinib—FLT3—lymph node—thymus cancer	9.87e-05	0.00145	CbGeAlD
Crizotinib—YES1—lung—thymus cancer	9.73e-05	0.00143	CbGeAlD
Crizotinib—STK35—lymph node—thymus cancer	9.67e-05	0.00142	CbGeAlD
Crizotinib—STK10—lung—thymus cancer	9.65e-05	0.00142	CbGeAlD
Crizotinib—TAOK3—lung—thymus cancer	9.61e-05	0.00141	CbGeAlD
Crizotinib—ABL2—lymph node—thymus cancer	9.42e-05	0.00138	CbGeAlD
Crizotinib—SRC—lung—thymus cancer	9.36e-05	0.00138	CbGeAlD
Crizotinib—BMP2K—lymph node—thymus cancer	9.31e-05	0.00137	CbGeAlD
Crizotinib—CSF1R—bone marrow—thymus cancer	9.28e-05	0.00136	CbGeAlD
Crizotinib—CSF1R—thyroid gland—thymus cancer	9.25e-05	0.00136	CbGeAlD
Crizotinib—PTK2B—lymph node—thymus cancer	8.99e-05	0.00132	CbGeAlD
Crizotinib—RIPK2—lymph node—thymus cancer	8.91e-05	0.00131	CbGeAlD
Crizotinib—ABL1—cardiac atrium—thymus cancer	8.69e-05	0.00128	CbGeAlD
Crizotinib—EPHA4—lymph node—thymus cancer	8.62e-05	0.00127	CbGeAlD
Crizotinib—ABL1—pituitary gland—thymus cancer	8.49e-05	0.00125	CbGeAlD
Crizotinib—MAP3K2—lymph node—thymus cancer	8.45e-05	0.00124	CbGeAlD
Crizotinib—CSF1R—lung—thymus cancer	8.41e-05	0.00124	CbGeAlD
Crizotinib—TBK1—lymph node—thymus cancer	8.28e-05	0.00122	CbGeAlD
Crizotinib—PTK2—lymph node—thymus cancer	8.28e-05	0.00122	CbGeAlD
Crizotinib—TYK2—lymph node—thymus cancer	8.22e-05	0.00121	CbGeAlD
Crizotinib—IRAK1—lymph node—thymus cancer	8.11e-05	0.00119	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—thymus cancer	8.05e-05	0.00118	CbGeAlD
Crizotinib—RPS6KB1—lymph node—thymus cancer	7.96e-05	0.00117	CbGeAlD
Crizotinib—LCK—lymph node—thymus cancer	7.91e-05	0.00116	CbGeAlD
Crizotinib—FGR—lymph node—thymus cancer	7.91e-05	0.00116	CbGeAlD
Crizotinib—AXL—lymph node—thymus cancer	7.88e-05	0.00116	CbGeAlD
Crizotinib—SLK—lymph node—thymus cancer	7.59e-05	0.00111	CbGeAlD
Crizotinib—EPHB4—lymph node—thymus cancer	7.53e-05	0.00111	CbGeAlD
Crizotinib—JAK2—lymph node—thymus cancer	7.48e-05	0.0011	CbGeAlD
Crizotinib—EPHA2—lymph node—thymus cancer	7.39e-05	0.00109	CbGeAlD
Crizotinib—ABL1—bone marrow—thymus cancer	7.33e-05	0.00108	CbGeAlD
Crizotinib—ABL1—thyroid gland—thymus cancer	7.32e-05	0.00107	CbGeAlD
Crizotinib—MAP3K3—lymph node—thymus cancer	7.21e-05	0.00106	CbGeAlD
Crizotinib—MAP4K5—lymph node—thymus cancer	7.21e-05	0.00106	CbGeAlD
Crizotinib—TEK—lymph node—thymus cancer	7.21e-05	0.00106	CbGeAlD
Crizotinib—EPHB6—lymph node—thymus cancer	6.89e-05	0.00101	CbGeAlD
Crizotinib—CYP3A5—hematopoietic system—thymus cancer	6.7e-05	0.000984	CbGeAlD
Crizotinib—YES1—lymph node—thymus cancer	6.66e-05	0.000978	CbGeAlD
Crizotinib—ABL1—lung—thymus cancer	6.64e-05	0.000976	CbGeAlD
Crizotinib—STK10—lymph node—thymus cancer	6.6e-05	0.000969	CbGeAlD
Crizotinib—TAOK3—lymph node—thymus cancer	6.57e-05	0.000966	CbGeAlD
Crizotinib—SRC—lymph node—thymus cancer	6.4e-05	0.000941	CbGeAlD
Crizotinib—CSF1R—lymph node—thymus cancer	5.75e-05	0.000845	CbGeAlD
Crizotinib—CYP3A4—hematopoietic system—thymus cancer	5.03e-05	0.000738	CbGeAlD
Crizotinib—ABL1—lymph node—thymus cancer	4.54e-05	0.000668	CbGeAlD
Crizotinib—CYP3A5—lung—thymus cancer	3.89e-05	0.000572	CbGeAlD
Crizotinib—ABCB1—hematopoietic system—thymus cancer	3.56e-05	0.000523	CbGeAlD
Crizotinib—ABCB1—epithelium—thymus cancer	3.25e-05	0.000478	CbGeAlD
Crizotinib—ABCB1—pituitary gland—thymus cancer	2.64e-05	0.000388	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—thymus cancer	2.5e-05	0.000368	CbGeAlD
Crizotinib—ABCB1—bone marrow—thymus cancer	2.28e-05	0.000335	CbGeAlD
Crizotinib—ABCB1—thyroid gland—thymus cancer	2.27e-05	0.000334	CbGeAlD
Crizotinib—ABCB1—lung—thymus cancer	2.07e-05	0.000304	CbGeAlD
Crizotinib—ABCB1—lymph node—thymus cancer	1.41e-05	0.000208	CbGeAlD
Crizotinib—LCK—Innate Immune System—KIT—thymus cancer	7.44e-06	0.000131	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAML2—thymus cancer	7.4e-06	0.00013	CbGpPWpGaD
Crizotinib—JAK2—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	7.39e-06	0.00013	CbGpPWpGaD
Crizotinib—LCK—DAP12 interactions—AKT1—thymus cancer	7.3e-06	0.000129	CbGpPWpGaD
Crizotinib—LCK—Signaling by FGFR in disease—AKT1—thymus cancer	7.3e-06	0.000129	CbGpPWpGaD
Crizotinib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	7.3e-06	0.000129	CbGpPWpGaD
Crizotinib—LCK—Signaling by EGFR—AKT1—thymus cancer	7.24e-06	0.000127	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL2—thymus cancer	7.23e-06	0.000127	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TP53—thymus cancer	7.23e-06	0.000127	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	7.21e-06	0.000127	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KIT—thymus cancer	7.19e-06	0.000126	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—AKT1—thymus cancer	7.18e-06	0.000126	CbGpPWpGaD
Crizotinib—LCK—Signaling by EGFR in Cancer—AKT1—thymus cancer	7.18e-06	0.000126	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL2—thymus cancer	7.15e-06	0.000126	CbGpPWpGaD
Crizotinib—LCK—Signaling by PDGF—AKT1—thymus cancer	7.14e-06	0.000126	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KIT—thymus cancer	7.14e-06	0.000126	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—IL2—thymus cancer	7.09e-06	0.000125	CbGpPWpGaD
Crizotinib—YES1—Immune System—KIT—thymus cancer	7.09e-06	0.000125	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—IL2—thymus cancer	7.06e-06	0.000124	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD8A—thymus cancer	7.04e-06	0.000124	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD8A—thymus cancer	7.01e-06	0.000123	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CD4—thymus cancer	7.01e-06	0.000123	CbGpPWpGaD
Crizotinib—JAK2—Platelet activation, signaling and aggregation—AKT1—thymus cancer	6.98e-06	0.000123	CbGpPWpGaD
Crizotinib—SRC—Downstream signal transduction—AKT1—thymus cancer	6.98e-06	0.000123	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR—AKT1—thymus cancer	6.94e-06	0.000122	CbGpPWpGaD
Crizotinib—SRC—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	6.94e-06	0.000122	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CD4—thymus cancer	6.94e-06	0.000122	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAML2—thymus cancer	6.93e-06	0.000122	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CD4—thymus cancer	6.91e-06	0.000122	CbGpPWpGaD
Crizotinib—SRC—Signaling by ERBB2—AKT1—thymus cancer	6.91e-06	0.000122	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CD4—thymus cancer	6.9e-06	0.000121	CbGpPWpGaD
Crizotinib—CDK7—Disease—CD4—thymus cancer	6.78e-06	0.000119	CbGpPWpGaD
Crizotinib—LCK—B Cell Activation—AKT1—thymus cancer	6.76e-06	0.000119	CbGpPWpGaD
Crizotinib—BLK—Immune System—CD4—thymus cancer	6.74e-06	0.000119	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KIT—thymus cancer	6.72e-06	0.000118	CbGpPWpGaD
Crizotinib—FGR—Immune System—CD4—thymus cancer	6.72e-06	0.000118	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CD4—thymus cancer	6.66e-06	0.000117	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KIT—thymus cancer	6.64e-06	0.000117	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—IL2—thymus cancer	6.64e-06	0.000117	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD8A—thymus cancer	6.59e-06	0.000116	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KIT—thymus cancer	6.58e-06	0.000116	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KIT—thymus cancer	6.53e-06	0.000115	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CD4—thymus cancer	6.5e-06	0.000114	CbGpPWpGaD
Crizotinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	6.47e-06	0.000114	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL2—thymus cancer	6.47e-06	0.000114	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR in disease—AKT1—thymus cancer	6.47e-06	0.000114	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL2—thymus cancer	6.45e-06	0.000113	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR—AKT1—thymus cancer	6.41e-06	0.000113	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—AKT1—thymus cancer	6.39e-06	0.000112	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL2—thymus cancer	6.35e-06	0.000112	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR in Cancer—AKT1—thymus cancer	6.35e-06	0.000112	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL2—thymus cancer	6.33e-06	0.000111	CbGpPWpGaD
Crizotinib—SRC—Signaling by PDGF—AKT1—thymus cancer	6.32e-06	0.000111	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KIT—thymus cancer	6.32e-06	0.000111	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL2—thymus cancer	6.2e-06	0.000109	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—thymus cancer	6.19e-06	0.000109	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL2—thymus cancer	6.18e-06	0.000109	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—AKT1—thymus cancer	6.12e-06	0.000108	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—AKT1—thymus cancer	6.12e-06	0.000108	CbGpPWpGaD
Crizotinib—SRC—Membrane Trafficking—AKT1—thymus cancer	6.11e-06	0.000108	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—AKT1—thymus cancer	6.11e-06	0.000108	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—thymus cancer	6.11e-06	0.000107	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—AKT1—thymus cancer	6.11e-06	0.000107	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	6.08e-06	0.000107	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAML2—thymus cancer	6.07e-06	0.000107	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—thymus cancer	6.06e-06	0.000107	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—thymus cancer	6.06e-06	0.000107	CbGpPWpGaD
Crizotinib—TYK2—Disease—KIT—thymus cancer	6.03e-06	0.000106	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—AKT1—thymus cancer	6e-06	0.000106	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KIT—thymus cancer	5.92e-06	0.000104	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KIT—thymus cancer	5.84e-06	0.000103	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—AKT1—thymus cancer	5.83e-06	0.000103	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IL2—thymus cancer	5.81e-06	0.000102	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—AKT1—thymus cancer	5.81e-06	0.000102	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD8A—thymus cancer	5.77e-06	0.000102	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—AKT1—thymus cancer	5.76e-06	0.000101	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—AKT1—thymus cancer	5.75e-06	0.000101	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—thymus cancer	5.74e-06	0.000101	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	5.73e-06	0.000101	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CD4—thymus cancer	5.69e-06	0.0001	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—AKT1—thymus cancer	5.68e-06	0.0001	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KIT—thymus cancer	5.59e-06	9.83e-05	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—AKT1—thymus cancer	5.54e-06	9.75e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD4—thymus cancer	5.5e-06	9.67e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD4—thymus cancer	5.46e-06	9.61e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD4—thymus cancer	5.42e-06	9.54e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KIT—thymus cancer	5.42e-06	9.53e-05	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—AKT1—thymus cancer	5.41e-06	9.53e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAML2—thymus cancer	5.37e-06	9.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—AKT1—thymus cancer	5.33e-06	9.38e-05	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—AKT1—thymus cancer	5.31e-06	9.34e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—AKT1—thymus cancer	5.31e-06	9.34e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KIT—thymus cancer	5.29e-06	9.3e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KIT—thymus cancer	5.26e-06	9.26e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—AKT1—thymus cancer	5.26e-06	9.25e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—thymus cancer	5.25e-06	9.24e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—AKT1—thymus cancer	5.23e-06	9.2e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—AKT1—thymus cancer	5.16e-06	9.08e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IL2—thymus cancer	5.15e-06	9.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD4—thymus cancer	5.14e-06	9.05e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—AKT1—thymus cancer	5.12e-06	9e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—AKT1—thymus cancer	5.12e-06	9e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD8A—thymus cancer	5.11e-06	8.99e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL2—thymus cancer	5.06e-06	8.9e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CD4—thymus cancer	5.04e-06	8.86e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL2—thymus cancer	5.03e-06	8.84e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD4—thymus cancer	4.99e-06	8.78e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL2—thymus cancer	4.99e-06	8.78e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—AKT1—thymus cancer	4.98e-06	8.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KIT—thymus cancer	4.95e-06	8.7e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—AKT1—thymus cancer	4.85e-06	8.53e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—AKT1—thymus cancer	4.84e-06	8.52e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD4—thymus cancer	4.84e-06	8.51e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL2—thymus cancer	4.73e-06	8.32e-05	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—AKT1—thymus cancer	4.73e-06	8.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—AKT1—thymus cancer	4.71e-06	8.29e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL2—thymus cancer	4.68e-06	8.23e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KIT—thymus cancer	4.65e-06	8.18e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—AKT1—thymus cancer	4.64e-06	8.17e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CD4—thymus cancer	4.61e-06	8.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL2—thymus cancer	4.59e-06	8.08e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—thymus cancer	4.59e-06	8.08e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KIT—thymus cancer	4.58e-06	8.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KIT—thymus cancer	4.57e-06	8.04e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—thymus cancer	4.55e-06	8.01e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—thymus cancer	4.53e-06	7.98e-05	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—AKT1—thymus cancer	4.46e-06	7.85e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—AKT1—thymus cancer	4.44e-06	7.81e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—AKT1—thymus cancer	4.41e-06	7.75e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—AKT1—thymus cancer	4.4e-06	7.75e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KIT—thymus cancer	4.35e-06	7.65e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—AKT1—thymus cancer	4.34e-06	7.63e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KIT—thymus cancer	4.33e-06	7.62e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—AKT1—thymus cancer	4.29e-06	7.55e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—AKT1—thymus cancer	4.28e-06	7.52e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	4.26e-06	7.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—thymus cancer	4.26e-06	7.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KIT—thymus cancer	4.22e-06	7.42e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2—thymus cancer	4.19e-06	7.38e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2—thymus cancer	4.17e-06	7.33e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—AKT1—thymus cancer	4.16e-06	7.31e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—thymus cancer	4.15e-06	7.31e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—thymus cancer	4.11e-06	7.23e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—thymus cancer	4.06e-06	7.15e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—thymus cancer	4.04e-06	7.11e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—thymus cancer	4.02e-06	7.08e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KIT—thymus cancer	4e-06	7.04e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—thymus cancer	3.93e-06	6.92e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—AKT1—thymus cancer	3.92e-06	6.9e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—AKT1—thymus cancer	3.92e-06	6.9e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—AKT1—thymus cancer	3.9e-06	6.87e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AKT1—thymus cancer	3.88e-06	6.82e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—AKT1—thymus cancer	3.85e-06	6.77e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KIT—thymus cancer	3.84e-06	6.75e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—AKT1—thymus cancer	3.83e-06	6.74e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—thymus cancer	3.81e-06	6.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—thymus cancer	3.81e-06	6.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—thymus cancer	3.78e-06	6.66e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—thymus cancer	3.73e-06	6.57e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—thymus cancer	3.72e-06	6.54e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—thymus cancer	3.7e-06	6.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—AKT1—thymus cancer	3.67e-06	6.46e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—AKT1—thymus cancer	3.64e-06	6.41e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	3.6e-06	6.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—AKT1—thymus cancer	3.6e-06	6.33e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KIT—thymus cancer	3.54e-06	6.23e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKT1—thymus cancer	3.51e-06	6.17e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AKT1—thymus cancer	3.5e-06	6.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—thymus cancer	3.49e-06	6.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—thymus cancer	3.48e-06	6.12e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AKT1—thymus cancer	3.46e-06	6.09e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—thymus cancer	3.45e-06	6.06e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—thymus cancer	3.44e-06	6.06e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—thymus cancer	3.43e-06	6.04e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KIT—thymus cancer	3.42e-06	6.01e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—thymus cancer	3.38e-06	5.95e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—thymus cancer	3.36e-06	5.92e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—thymus cancer	3.35e-06	5.9e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—thymus cancer	3.33e-06	5.85e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—thymus cancer	3.31e-06	5.83e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—thymus cancer	3.31e-06	5.82e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—thymus cancer	3.27e-06	5.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—thymus cancer	3.24e-06	5.7e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—thymus cancer	3.22e-06	5.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KIT—thymus cancer	3.2e-06	5.63e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—thymus cancer	3.15e-06	5.55e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—thymus cancer	3.06e-06	5.38e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—thymus cancer	3.06e-06	5.38e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—thymus cancer	3.05e-06	5.36e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—thymus cancer	3e-06	5.28e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—thymus cancer	2.97e-06	5.22e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—thymus cancer	2.93e-06	5.16e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—thymus cancer	2.85e-06	5.01e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—thymus cancer	2.84e-06	4.99e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KIT—thymus cancer	2.8e-06	4.93e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—thymus cancer	2.79e-06	4.91e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—thymus cancer	2.74e-06	4.83e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—thymus cancer	2.73e-06	4.8e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—thymus cancer	2.73e-06	4.8e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—thymus cancer	2.71e-06	4.77e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—thymus cancer	2.7e-06	4.76e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—thymus cancer	2.7e-06	4.75e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—thymus cancer	2.68e-06	4.71e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—thymus cancer	2.64e-06	4.64e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—thymus cancer	2.57e-06	4.51e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—thymus cancer	2.54e-06	4.46e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—thymus cancer	2.52e-06	4.44e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—thymus cancer	2.51e-06	4.42e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—thymus cancer	2.49e-06	4.38e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KIT—thymus cancer	2.48e-06	4.36e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—thymus cancer	2.45e-06	4.31e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—thymus cancer	2.41e-06	4.25e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—thymus cancer	2.4e-06	4.23e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—thymus cancer	2.3e-06	4.05e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—thymus cancer	2.27e-06	4e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—thymus cancer	2.26e-06	3.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—thymus cancer	2.25e-06	3.96e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—thymus cancer	2.23e-06	3.92e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—thymus cancer	2.13e-06	3.75e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—thymus cancer	2.1e-06	3.69e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—thymus cancer	2.07e-06	3.64e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—thymus cancer	2.07e-06	3.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—thymus cancer	2.07e-06	3.63e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—thymus cancer	2.02e-06	3.55e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—thymus cancer	2.01e-06	3.53e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—thymus cancer	1.97e-06	3.47e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—thymus cancer	1.96e-06	3.46e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—thymus cancer	1.91e-06	3.36e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—thymus cancer	1.89e-06	3.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—thymus cancer	1.77e-06	3.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—thymus cancer	1.75e-06	3.08e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—thymus cancer	1.74e-06	3.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—thymus cancer	1.74e-06	3.07e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—thymus cancer	1.66e-06	2.92e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—thymus cancer	1.65e-06	2.91e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—thymus cancer	1.61e-06	2.83e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—thymus cancer	1.54e-06	2.72e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—thymus cancer	1.53e-06	2.69e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—thymus cancer	1.46e-06	2.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—thymus cancer	1.45e-06	2.54e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—thymus cancer	1.35e-06	2.38e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—thymus cancer	1.3e-06	2.29e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—thymus cancer	1.27e-06	2.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—thymus cancer	1.22e-06	2.15e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—thymus cancer	1.12e-06	1.97e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—thymus cancer	1.07e-06	1.88e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—thymus cancer	9.46e-07	1.66e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—thymus cancer	8.87e-07	1.56e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—thymus cancer	6.69e-07	1.18e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—thymus cancer	4.12e-07	7.26e-06	CbGpPWpGaD
